The Medicines Company Acquires Targanta

The Medicines Company Acquires Targanta

Client News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

WilmerHale client, The Medicines Company, announced yesterday that it had completed its acquisition of Targanta Therapeutics Corporation.

The Medicines Company completed the transaction through a cash tender offer followed by a short form merger. The Medicines Company paid Targanta stockholders $2.00 per share, net to the seller in cash, plus the contractual right to receive up to an additional $4.55 per share in contingent cash payments if specified regulatory and commercial milestones are achieved within agreed upon time periods.

With the consummation of the acquisition, Targanta has become a wholly owned subsidiary of The Medicines Company. Further details can be found by clicking here.

WilmerHale was legal advisor to The Medicines Company in this transaction, with a team including: partners David Redlick, Hal Leibowitz, Stuart Falber and Jeffrey Hermanson; counsels Marisa Murtagh and Jessica Lopez; and associates Dana Krueger and Erica Koenig.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel